Pheochromocytoma
Recent clinical, regulatory, research and industry developments relating to this disease.
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA)
- Q4 2028A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma
- Q4 2029A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
- Q1 2030Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Clinical MilestonesViewHide
- 2026-07-08A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic AlterationsResults expected Q4 2029
- 2026-06-10A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and ParagangliomaResults expected Q4 2028
- 2026-04-24Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaResults expected Q1 2030
- 2026-03-02Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA)Results expected Q1 2027
- 2026-07-08ClinicalA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic AlterationsResults expected Q4 2029
- 2026-06-10ClinicalA Phase 2 Study of ONC206 in Advanced Pheochromocytoma and ParagangliomaResults expected Q4 2028
- 2026-04-24ClinicalLu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaResults expected Q1 2030
- 2026-03-02ClinicalExploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA)Results expected Q1 2027
- 2026-02-12ClinicalA Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)Results posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes6
- Adrenal Gland Neoplasms2
- Pheochromocytoma2
- Adrenal Cortex Neoplasms1
- Adrenocortical Carcinoma1
- Paraganglioma1
- Tumor Microenvironment1
Leading journals2
- Annals of oncology : official journal of the European Society for Medical Oncology1
- Endocrine reviews1
Leading researchers8
- Assie G1
- Baudin E1
- Berruti A1
- Calsina B1
- Clifton-Bligh R1
- de Krijger R1
- de la Fouchardiere C1
- Eisenhofer G1
Affiliations (unnormalised)6
- Cancer Genetics Laboratory1
- Centre Léon Bérard1
- Department of Clinical and Biological Sciences1
- Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine1
- Eunice Kennedy Shriver National Institute of Child Health and Human Development1
- Familiar Cancer Clinical Unit1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.